Save
Serum neurofilament light chain levels and cortical pathology in multiple sclerosis: 5-year longitudinal study
Author(s): ,
R. Zivadinov
Affiliations:
Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York; Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, State University of New York
,
M. Ramanathan
Affiliations:
Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, United States
,
C. Barro
Affiliations:
Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel
,
J. Hagemeier
Affiliations:
Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York
,
D. Jakimovski
Affiliations:
Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York
,
N. Bergsland
Affiliations:
Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York
,
D. Tomic
Affiliations:
Novartis Pharma AG, Basel, Switzerland
,
H. Kropshofer
Affiliations:
Novartis Pharma AG, Basel, Switzerland
,
D. Leppert
Affiliations:
Novartis Pharma AG, Basel, Switzerland
,
Z. Michalak
Affiliations:
Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel
,
M.G. Dwyer
Affiliations:
Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York
,
R.H.B. Benedict
Affiliations:
Jacobs MS Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, United States
,
B. Weinstock-Guttman
Affiliations:
Jacobs MS Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, United States
J. Kuhle
Affiliations:
Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel
ECTRIMS Online Library. Zivadinov R. Oct 12, 2018; 228128; P1750
Prof. Dr. Robert Zivadinov
Prof. Dr. Robert Zivadinov
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: P1750

Type: Poster Sessions

Abstract Category: N/A

Background: The association between serum neurofilament light chain levels (sNfL) and cortical pathology in patients with multiple sclerosis (MS) was not previously investigated.
Objective: To identify the role of sNfL in development of cortical pathology, as measured by cortical atrophy and leptomeningeal contrast-enhancement (LM CE) in clinically isolated syndrome (CIS) and MS patients, as compared to healthy individuals (HI).
Materials and methods: The study included 127 MS patients, 20 clinically isolated syndrome (CIS) patients and 52 HI. The MS cohort was composed of 85 relapsing-remitting MS (RR) and 42 progressive (PMS) patients. At baseline and 5 years follow-up, all participants underwent standardized 3T MRI and serum sampling. The evolution of brain atrophy, and accumulation of lesion volumes (LVs) was measured. LMCE was assessed using subtraction imaging between 3D-FLAIR pre- and post-contrast sequences. sNfL levels were measured by Simoa assay in pg/ml. Multiple linear regression analyses using age- and sex-adjusted sNfL levels were performed.
Results: MS patients had higher baseline sNfL levels compared to HI (25.8 vs. 18.4, p=0.016), whereas there were no differences between CIS patients and HI (21.1 vs.18.4, p=0.489). PMS patients had significantly higher change of sNfL over 5 years, compared to RRMS (+7.6 vs. -0.6, p=0.049). In MS/CIS patients, higher baseline sNfL predicted higher percentage brain volume change (p< 0.001), percentage cortical volume change (PCVC) (p=0.001), absolute accumulation in gadolinium LV (p< 0.001), T2-LV (p=0.002), T1-LV (p=0.032) and enlargement of lateral ventricles (p=0.014) over 5 years. Higher absolute change in sNfL over 5 years was significantly associated with higher absolute accumulation in gadolinium LV (p< 0.001) and PCVC (p=0.017) in RRMS patients, and with T2-LV accumulation in HI (p=0.034). No significant association between LMCE and sNfL was detected over 5 years.
Conclusion: Higher sNfL levels are associated with cortical pathology and accumulation of LVs in MS/CIS patients over 5 years.
Disclosure: This study was in part funded by Novartis Pharma AG, Basel, Switzerland.
Robert Zivadinov received personal compensation from EMD Serono, Genzyme-Sanofi, Claret Medical, Celgene and Novartis for speaking and consultant fees. He received financial support for research activities from Genzyme-Sanofi, Novartis, Celgene, Claret Medical, Intekrin-Coherus, Protembis and Qunitiles/IMS.
Dejan Jakimovski, Jesper Hagemeier, Niels Bergsland and Zuzanna Michalak have nothing to disclose.
Murali Ramanathan received research funding or consulting fees from EMD Serono, Biogen Idec, Pfizer Inc, the National Multiple Sclerosis Society, the Department of Defense, Jog for the Jake Foundation, the National Institutes of Health and National Science Foundation. He received compensation for serving as an Editor from the American Association of Pharmaceutical Scientists.
Christian Barro received conference travel grant from Teva and Novartis
Michael G. Dwyer has received consultant fees from Claret Medical and EMD Serono.
Davorka Tomic, Harald Kropshofer and David Leppert are employees of Novartis Pharma AG, Basel, Switzerland.
Ralph RH. Benedict received personal compensation from Neurocog Trials, Genentech, Roche, Takeda, Abbvie, Novartis, Sanofi and EMD Serono for speaking and consultant fees. He received financial support for research activities from Genzyme, Biogen, Mallinckrodt.
Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis and Acorda. Dr Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis, Acorda.
Jens Kuhle received speaker fees, research support, travel support, and/or served on advisory boards by ECTRIMS, Swiss MS Society, Swiss National Research Foundation, (320030_160221), University of Basel, Bayer, Biogen, Genzyme, Merck, Novartis, Protagen AG, Roche, Teva.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings